The Administration Seems to Be Moving the MFN Push from Medicaid to Medicare. Buckle Up
Shares:
Near-Term Programming Note: Cost Curve is off tomorrow, back Friday for AbbVie earnings and whatever other fun befalls us in the next 48 hours. Long-Term Programming Note: I plan to
Inflection Point The thorniest problem in biopharmaceuticals is the growing conflict between cost-effectiveness and budget impact. In other words, we increasingly have weapons against disease that are, objectively and
Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv